We are currently recruiting for the following clinical trials:

Suven CTP3S1502HT6: A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride.

ADEPT-3 CN0120056  KAR 033 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimer’s Disease Dementia.

ProMis A Phase 1b, Double-Blind, Placebo Controlled, Multiple Ascending Dose of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy of PMN310 in Patients With Early Alzheimer’s Disease.

CN0120056 (ADEPT 4) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease.

ML-007C-MA-221 entitled “A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis”

More Studies Being Added Soon!

= Trial is Active and Recruiting